LENZ Therapeutics, Inc. 10% holder RA Capital Management, L.P. sells $9.13M in LENZ shares
An open-market sale on Oct 29, reported to the SEC on Nov 2, not marked as part of a 10b5-1 plan. Information only, not investment advice.
LENZ Therapeutics, Inc. (LENZ) 10% owner RA Capital Management, L.P. sold about $9.1 million of stock on Oct 29: 2,718,684 shares at an average of $3.36, according to an SEC filing.
The filing reports the shares as held indirectly, for example through a trust or a fund. After the trade, the filing lists 1,460,139 shares held.
The filing came 4 days after the trade.
The numbers below are taken from the Form 4 as filed with the SEC.
| Company | LENZ Therapeutics, Inc. (LENZ) |
|---|---|
| Insider | RA Capital Management, L.P. |
| Role | 10% owner |
| Transaction | Open-market sale (code S) |
| Shares | 2,718,684 |
| Average price | $3.36 |
| Value | $9,134,778 |
| Trade date | Oct 29, 2026 |
| Filed with the SEC | Nov 2, 2026, 5:44 PM ET |
| Shares held after | 1,460,139 |
| Ownership | Indirect |
| Rule 10b5-1 plan | Not marked in the filing |
View this Form 4 in Insider Stock Trader
See all insider activity at LENZ Therapeutics, Inc. · See all the latest insider trades
Source: SEC Form 4. Information only, not investment advice. Not affiliated with or endorsed by the U.S. Securities and Exchange Commission.
Related Articles
- Insider Trading News
RA Capital Management, L.P., a director at Bambusa Therapeutics, Inc., buys $46.6M of stock
- Insider Trading News
Ligand Pharmaceuticals Inc insider Jason Aryeh sells $676,158 in LGND shares
- Insider Trading News
10% owner Venrock Healthcare Capital Partners III, L.P. buys $223,820 of Lycia Therapeutics, Inc. stock
- Insider Trading News
Three insiders buy Bambusa Therapeutics, Inc. shares, $58.6M in total
- Insider Trading News
Christine Ring, a chief legal officer at Nurix Therapeutics, Inc., sells $103,986 of stock
